Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Lexaria Bioscience, a Kelowna, Canada-based company that develops drug delivery platforms, is seeking a listing on the Nasdaq. The company is currently listed on the Over-the-Counter Markets under the ticker "LXRP," as well as the Canadian Securities Exchange under the ticker symbol "LXX."
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Social traders
| Latest market close | $2.45 |
|---|---|
| 52-week range | $1.85 - $7.15 |
| 50-day moving average | $2.89 |
| 200-day moving average | $3.23 |
| Wall St. target price | $15.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-1.29 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.45 from 2022-09-30
| 1 week (2022-09-23) | -0.81% |
|---|---|
| 1 month (2022-09-02) | -17.92% |
| 3 months (2022-07-01) | -11.23% |
| 6 months (2022-03-29) | N/A |
| 1 year (2021-10-01) | -61.60% |
|---|---|
| 2 years (2020-10-02) | 880.00% |
| 3 years (2019-10-02) | 483.33% |
| 5 years (2017-10-02) | 456.82% |
| Revenue TTM | $175,268 |
|---|---|
| Gross profit TTM | $547,392 |
| Return on assets TTM | -45.55% |
| Return on equity TTM | -74.8% |
| Profit margin | 0% |
| Book value | $1.54 |
| Market capitalisation | $14.7 million |
TTM: trailing 12 months
We're not expecting Lexaria Bioscience to pay a dividend over the next 12 months.
You may also wish to consider:
Lexaria Bioscience's shares were split on a 1:30 basis on 12 January 2021. So if you had owned 30 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Lexaria Bioscience shares – just the quantity. However, indirectly, the new 2900% higher share price could have impacted the market appetite for Lexaria Bioscience shares which in turn could have impacted Lexaria Bioscience's share price.
Over the last 12 months, Lexaria Bioscience's shares have ranged in value from as little as $1.85 up to $7.15. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Lexaria Bioscience's is 1.1578. This would suggest that Lexaria Bioscience's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
To put Lexaria Bioscience's beta into context you can compare it against those of similar companies.
Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's DehydraTECH has demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and in some instances with cannabinoids by 27x compared to standard industry formulations, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and others. DehydraTECH also deliver drugs effectively across the blood brain barrier. It operates a licensed in-house research laboratory and holds intellectual property portfolio with 23 patents granted and approximately 50 patents pending worldwide. Lexaria Bioscience Corp.
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.